Patients' characteristics at baseline and follow-up
| Demographics | All at baseline | Follow-up patients without HFNEF | Follow-up patients with HFNEF | p Value |
| Number of patients | 50 | 23 | 22 | NS |
| Gender, male/female | 37/13 | 20/3 | 14/8 | NS |
| Follow-up period, months | 72 | 72 (51–76) | 71 (55–80) | NS |
| NYHA | 38 II/3 III/1 IV | 23 I | 17 II/5 III | <0.001 |
| Hospitalisation with HF, n | 42 | 1 | 7 | NS |
| Days in hospital | 4 | 7.0 (4.0–8.0) | NS | |
| NT-proBNP pmol/l | 29.2 (10.2–49.8) | 7.3 (4.2–11.9) | 19.9 (10.6–24.1) | 0.006 |
| Medications, n | ||||
| β-Blockers | 12 | 1 | 2 | NS |
| RAAS inhibitors | 21 | 1 | 4 | NS |
| Diuretics | 11 | 0 | 0 | NS |
p<0.05 follow-up patients without HFNEF versus follow-up patients with HFNEF.
Values are expressed as the median (25–75% quartile).
HFNEF, heart failure with a normal ejection fraction; NS, non-significant; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RAAS, renin–angiotensin–aldosterone system.